NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Cellular & Molecular Immunology

• Publication date

  2014-10-13

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/cmi.2014.91PMID 25308752PMCID PMC4654321
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner.

  2016cited by this paper
• Cancer exosomes and NKG2D receptor-ligand interactions: impairing NKG2D-mediated cytotoxicity and anti-tumour immune surveillance.

  2014cited by this paper
• Cancer-Induced Alterations of NK-Mediated Target Recognition: Current and Investigational Pharmacological Strategies Aiming at Restoring NK-Mediated Anti-Tumor Activity

  2014cited by this paper
• Effect of tumor cells and tumor microenvironment on NK‐cell function

  2014cited by this paper
• p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells

  2013cited by this paper
• Therapeutic Depletion of Natural Killer Cells Controls Persistent Infection

  2013cited by this paper
• The liver works as a school to educate regulatory immune cells

  2013cited by this paper
• Activating natural cytotoxicity receptors of natural killer cells in cancer and infection.

  2013cited by this paper
• Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells

  2013cited by this paper
• Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells.

  2013cited by this paper
• Innate and adaptive immune cells in the tumor microenvironment

  2013cited by this paper
• Blocking the natural killer cell inhibitory receptor NKG2A increases activity of human natural killer cells and clears hepatitis B virus infection in mice.

  2013cited by this paper
• Fibroblast growth factor-2 enhances NK sensitivity of hepatocellular carcinoma cells

  2013cited by this paper
• Enhanced interaction between natural killer cells and lung cancer cells: involvement in gefitinib-mediated immunoregulation

  2013cited by this paper
• Population-Attributable Fractions of Risk Factors for Hepatocellular Carcinoma in the United States

  2013cited by this paper
• Distribution of several activating and inhibitory receptors on CD3(-)CD56(+) NK cells in regional lymph nodes of melanoma patients.

  2013cited by this paper
• Memory NK cells: why do they reside in the liver?

  2013cited by this paper
• Regulation of ligands for the NKG2D activating receptor.

  2013cited by this paper
• Loss of immunity‐supported senescence enhances susceptibility to hepatocellular carcinogenesis and progression in Toll‐like receptor 2‐deficient mice

  2013cited by this paper
• Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell–mediated deletion

  2013cited by this paper
• Tumor microenviroment and hepatocellular carcinoma metastasis

  2013cited by this paper
• NK cells in immunotolerant organs

  2013cited by this paper
• Human NK Cells Selective Targeting of Colon Cancer–Initiating Cells: A Role for Natural Cytotoxicity Receptors and MHC Class I Molecules

  2013cited by this paper
• Comprehensive analysis of the percentage of surface receptors and cytotoxic granules positive natural killer cells in patients with pancreatic cancer, gastric cancer, and colorectal cancer

  2013cited by this paper
• Differential Inhibition of the TGF-β Signaling Pathway in HCC Cells Using the Small Molecule Inhibitor LY2157299 and the D10 Monoclonal Antibody against TGF-β Receptor Type II

  2013cited by this paper
• Monocyte/macrophage‐elicited natural killer cell dysfunction in hepatocellular carcinoma is mediated by CD48/2B4 interactions

  2013cited by this paper
• Cancer-Associated Fibroblasts from Hepatocellular Carcinoma Promote Malignant Cell Proliferation by HGF Secretion

  2013cited by this paper
• Liver-resident NK cells confer adaptive immunity in skin-contact inflammation.

  2013cited by this paper
• Tumor-Primed NK Cells: Waiting for the Green Light

  2013cited by this paper
• Increased Circulating Th17 Cells after Transarterial Chemoembolization Correlate with Improved Survival in Stage III Hepatocellular Carcinoma: A Prospective Study

  2013cited by this paper
• Osteopontin splice variants expressed by breast tumors regulate monocyte activation via MCP-1 and TGF-β1

  2013cited by this paper
• Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity.

  2013cited by this paper
• Hematological Malignancies Escape from NK Cell Innate Immune Surveillance: Mechanisms and Therapeutic Implications

  2012cited by this paper
• Hepatocellular carcinoma-associated fibroblasts trigger NK cell dysfunction via PGE2 and IDO.

  2012cited by this paper
• Identification and functional analysis of ligands for natural killer cell activating receptors in colon carcinoma.

  2012cited by this paper
• NK cell MHC class I specific receptors (KIR): from biology to clinical intervention.

  2012cited by this paper
• A novel mechanism for cancer cells to evade immune attack by NK cells

  2012cited by this paper
• Impaired intrahepatic natural killer cell cytotoxic function in chronic hepatitis C virus infection

  2012cited by this paper
• TGF-β1 Down-Regulation of NKG2D/DAP10 and 2B4/SAP Expression on Human NK Cells Contributes to HBV Persistence

  2012cited by this paper
• A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission.

  2012cited by this paper
• Fibroblast growth factor‐2 enhances NK sensitivity of hepatocellular carcinoma cells

  2012cited by this paper
• Soluble MICA and a MICA Variation as Possible Prognostic Biomarkers for HBV-Induced Hepatocellular Carcinoma

  2012cited by this paper
• Associations between infiltrating lymphocyte subsets and hepatocellular carcinoma.

  2012cited by this paper
• A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis.

  2012cited by this paper
• Viral antigen mediated NKp46 activation of NK cells results in tumor rejection via NK-DC crosstalk

  2012cited by this paper
• HLA‐E/β2 microglobulin overexpression in colorectal cancer is associated with recruitment of inhibitory immune cells and tumor progression

  2012cited by this paper
• Targeting NKG2D in tumor surveillance

  2012cited by this paper
• Epidemiology of viral hepatitis and hepatocellular carcinoma.

  2012cited by this paper
• NKG2D ligand tumor expression and association with clinical outcome in early breast cancer patients: an observational study

  2012cited by this paper
• Hepatitis B viral load and risk of HBV-related liver disease: from East to West?

  2012cited by this paper
• A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma.

  2012cited by this paper
• Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity.

  2012cited by this paper
• Reduced NKG2D ligand expression in hepatocellular carcinoma correlates with early recurrence.

  2012cited by this paper
• Human Tumour Immune Evasion via TGF-β Blocks NK Cell Activation but Not Survival Allowing Therapeutic Restoration of Anti-Tumour Activity

  2011cited by this paper
• NK cells: immune cross-talk and therapeutic implications.

  2011cited by this paper
• Kinase activation profile associated with TGF-β-dependent migration of HCC cells: a preclinical study

  2011cited by this paper
• Human tumor‐induced and naturally occurring Treg cells differentially affect NK cells activated by either IL‐2 or target cells

  2011cited by this paper
• New immune therapy targets tumor-associated environment: from bone marrow to tumor site

  2011cited by this paper
• CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia

  2011cited by this paper
• Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity.

  2011cited by this paper
• Viral load reduction improves activation and function of natural killer cells in patients with chronic hepatitis B.

  2011cited by this paper
• Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma

  2011cited by this paper
• Possible association of decreased NKG2D expression levels and suppression of the activity of natural killer cells in patients with colorectal cancer

  2011cited by this paper
• Hepatocellular carcinoma.

  2011cited by this paper
• Novel role for STAT3 in transcriptional regulation of NK immune cell targeting receptor MICA on cancer cells.

  2011cited by this paper
• Human NK cells in acute myeloid leukaemia patients: analysis of NK cell-activating receptors and their ligands

  2011cited by this paper
• Hepatocellular carcinoma (HCC): a global perspective.

  2010cited by this paper
• T cell immunoglobulin- and mucin-domain-containing molecule-3 (Tim-3) mediates natural killer cell suppression in chronic hepatitis B.

  2010cited by this paper
• Prognostic value of interleukin 2 and interleukin 15 in peritumoral hepatic tissues for patients with hepatitis B-related hepatocellular carcinoma after curative resection

  2010cited by this paper
• Blockade of Immunosuppressive Cytokines Restores NK Cell Antiviral Function in Chronic Hepatitis B Virus Infection

  2010cited by this paper
• Role of chemokines in the biology of natural killer cells.

  2010cited by this paper
• IL‐2‐activated haploidentical NK cells restore NKG2D‐mediated NK‐cell cytotoxicity in neuroblastoma patients by scavenging of plasma MICA

  2010cited by this paper
• Cell Death and Fibrogenesis

  2010cited by this paper
• Natural killer cells and malignant haemopathies: a model for the interaction of cancer with innate immunity

  2010cited by this paper
• World Gastroenterology Organisation Guideline. Hepatocellular carcinoma (HCC): a global perspective.

  2010cited by this paper
• Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patients.

  2010cited by this paper
• Diminished absolute counts of CD56dim and CD56bright natural killer cells in peripheral blood from Egyptian patients with hepatocellular carcinoma.

  2009cited by this paper
• Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity

  2009cited by this paper
• Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor

  2009cited by this paper
• Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma.

  2009cited by this paper
• Low NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions

  2009cited by this paper
• The Lytic Potential of Human Liver NK Cells Is Restricted by Their Limited Expression of Inhibitory Killer Ig-Like Receptors1

  2009cited by this paper
• Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections.

  2009cited by this paper
• Obstructing Shedding of the Immunostimulatory MHC Class I Chain–Related Gene B Prevents Tumor Formation

  2009cited by this paper
• Fine characterization of intrahepatic NK cells expressing natural killer receptors in chronic hepatitis B and C.

  2009cited by this paper
• Tumor-associated MICA is shed by ADAM proteases.

  2008cited by this paper
• Functional impairment in circulating and intrahepatic NK cells and relative mechanism in hepatocellular carcinoma patients.

  2008cited by this paper
• NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy.

  2008cited by this paper
• Serum levels of soluble major histocompatibility complex (MHC) class I‐related chain A in patients with chronic liver diseases and changes during transcatheter arterial embolization for hepatocellular carcinoma

  2008cited by this paper
• Blockade of CD200 in the Presence or Absence of Antibody Effector Function: Implications for Anti-CD200 Therapy

  2008cited by this paper
• Opposing effects of interferon‐α and interferon‐γ on the expression of major histocompatibility complex class I chain‐related A in tumors

  2008cited by this paper
• Interleukin-15 improves cytotoxicity of natural killer cells via up-regulating NKG2D and cytotoxic effector molecule expression as well as STAT1 and ERK1/2 phosphorylation.

  2008cited by this paper
• Impaired T cell function and decreased natural killer activity in patients with liver cirrhosis and their significance in the development of hepatocellular carcinoma

  2007cited by this paper
• CD200 Expression on Tumor Cells Suppresses Antitumor Immunity: New Approaches to Cancer Immunotherapy

  2007cited by this paper
• Increased natural cytotoxicity receptor expression and relevant IL‐10 production in NK cells from chronically infected viremic HCV patients

  2007cited by this paper
• Hepatocellular carcinoma: epidemiology and molecular carcinogenesis.

  2007cited by this paper
• Liver: An organ with predominant innate immunity

  2007cited by this paper
• Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression.

  2006cited by this paper
• Anti-fibrotic activity of NK cells in experimental liver injury through killing of activated HSC.

  2006cited by this paper
• Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment.

  2006cited by this paper

• Evaluation of immuno-oncologic biomarkers and β-catenin expression in response of hepatocellular carcinomas to immunotherapy

  2026cites this paper
• NK cell infusion is well-tolerated and shows preliminary efficacy in patients with recurrent hepatocellular carcinoma post-liver transplantation : a phase I trial

  2026cites this paper
• The Male Predominance in HBV-Related Hepatocellular Carcinoma: Unraveling the Axis of Androgen Receptor, Viral Replication, and Immune Evasion via NKG2D Ligands

  2026cites this paper
• Advances in chimeric antigen receptor-natural killer cell therapy: from mechanisms and preclinical studies to clinical application

  2026cites this paper
• Depressive symptoms and immune depletion in Chinese patients with advanced hepatocellular carcinoma: a multicentre study on their correlation

  2025cites this paper
• CAR-NK cells with dual targeting of PD-L1 and MICA/B in lung cancer tumor models

  2025cites this paper
• CD96: immunoregulation and its role and prospect in immunotherapy of primary hepatocellular carcinoma.

  2025cites this paper
• Harnessing nanoparticles for reshaping tumor immune microenvironment of hepatocellular carcinoma

  2025cites this paper
• CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity

  2025cites this paper
• TFDP1 activates SPC25-mediated glutamine metabolism to repress anti-tumor immunity of NK cells in lung adenocarcinoma

  2025cites this paper
• The role of liver macrophages in viral liver pathogenesis

  2025cites this paper
• Radiofrequency Ablation and Immunotherapy: Orchestrating the Immune Microenvironment for Improved Hepatocellular Carcinoma Control

  2025cites this paper
• Viral-Track integrated single-cell RNA-sequencing reveals HBV lymphotropism and immunosuppressive microenvironment in HBV-associated hepatocellular carcinoma

  2025cites this paper
• Rendering NK Cells Antigen-Specific for the Therapy of Solid Tumours

  2025cites this paper
• Precision sniper for solid tumors: CAR-NK cell therapy

  2025cites this paper
• Natural Killer Cell‐Mediated Antitumor Immunity: Molecular Mechanisms and Clinical Applications

  2025cites this paper
• The role of natural killer cells in the immune response after liver transplantation.

  2025cites this paper
• CAR-NK cells in combination therapy against cancer: A potential paradigm

  2024cites this paper
• Pathway-enhanced Transformer-based robust model for quantifying cell types of origin of cell-free transcriptome

  2024cites this paper
• Therapeutic restoration of miR-126-3p as a multi-targeted strategy to modulate the liver tumor microenvironment

  2024cites this paper
• Post-transplant hepatitis B virus reactivation impacts the prognosis of patients with hepatitis B-related hepatocellular carcinoma: a dual-centre retrospective cohort study in China

  2024cites this paper
• Nanomedicines for reversing immunosuppressive microenvironment of hepatocellular carcinoma.

  2024cites this paper
• Increased Siglec-9/Siglec-9L interactions on NK cells predict poor HCC prognosis and present a targetable checkpoint for immunotherapy.

  2024cites this paper
• Epigenetic modification of hepatitis B virus infection and related hepatocellular carcinoma

  2024cites this paper
• Supercritical CO2 extracts of propolis inhibits tumor proliferation and Enhances the immunomodulatory activity via activating the TLR4-MAPK/NF-κB signaling pathway.

  2024cites this paper
• Single-cell RNA sequencing reveals anti-tumor potency of CD56+ NK cells and CD8+ T cells in humanized mice via PD-1 and TIGIT co-targeting

  2024cites this paper
• Evaluation of prognostic efficacy of liver immune status index in predicting postoperative outcomes in hepatocellular carcinoma patients: A multi‐institutional retrospective study

  2024cites this paper
• Natural killer cells in neuroblastoma: immunological insights and therapeutic perspectives

  2024cites this paper
• Peripheral NK cell phenotypic alteration and dysfunctional state post hepatitis B subviral particles stimulation in CHB patients: evading immune surveillance

  2024cites this paper
• Prognostic value of innate immune cell densities in patients with hepatocellular carcinoma after liver transplantation.

  2024cites this paper
• Association of HLA-G 3′UTR polymorphisms with hepatitis B virus infection in Tunisian population

  2024cites this paper
• Deciphering the role of KLRB1: a novel prognostic indicator in hepatocellular carcinoma

  2024cites this paper
• Dysfunction of type 1 and type 2 immune cells: a lesson from exhausted-like ILC2s and their activation-induced cell death

  2024cites this paper
• Galectin-3-ITGB1 Signaling Mediates Interleukin 10 Production of Hepatic Conventional Natural Killer Cells in Hepatitis B Virus Transgenic Mice and Correlates with Hepatocellular Carcinoma Progression in Patients

  2024cites this paper
• NK cell exhaustion in Wilson’s disease revealed by single-cell RNA sequencing predicts the prognosis of cholecystitis

  2024cites this paper
• RAC1high NK cell-based immunotherapy in hepatocellular carcinoma via STAT3-NKG2D axis.

  2024cites this paper
• Application and progress of CAR therapy on malignances: from CAR-T to CAR-NK

  2024cites this paper
• Lower NKG2D expression in hepatic natural killer cells predicts poorer prognosis for chronic hepatitis B patients with cirrhosis.

  2024cites this paper
• Exploring cellular immunotherapy platforms in multiple myeloma

  2024cites this paper
• Natural killer cells in sepsis: Friends or foes?

  2023cites this paper
• Interorgan communication with the liver: novel mechanisms and therapeutic targets

  2023cites this paper
• A circadian clock gene-related signature for predicting prognosis and its association with sorafenib response in hepatocellular carcinoma

  2023cites this paper
• IL‐21 collaborates with anti‐TIGIT to restore NK cell function in chronic HBV infection

  2023cites this paper
• A pan-cancer single-cell panorama of human natural killer cells.

  2023cites this paper
• Contribution of an Asian-prevalent HLA haplotype to the risk of HBV-related hepatocellular carcinoma

  2023cites this paper
• Novel chimeric antigen receptor targets and constructs for acute lymphoblastic leukemia: Moving beyond CD19

  2023cites this paper
• Integrated analysis of single-cell and bulk RNA-sequencing reveals tumor heterogeneity and a signature based on NK cell marker genes for predicting prognosis in hepatocellular carcinoma

  2023cites this paper
• Target immune components to circumvent sorafenib resistance in hepatocellular carcinoma.

  2023cites this paper
• Establishment of humanized mice and its application progress in cancer immunotherapy.

  2023cites this paper
• Synergistic therapeutic combination with a CAF inhibitor enhances CAR-NK-mediated cytotoxicity via reduction of CAF-released IL-6

  2023cites this paper
• Decreased DIO3OS Expression Predicts Poor Prognosis in Hepatocellular Carcinoma and is Associated with Immune Infiltration

  2023cites this paper
• The role of miR-155 on liver diseases by modulating immunity, inflammation and tumorigenesis.

  2023cites this paper
• The Roles of Epigenetic Regulation and the Tumor Microenvironment in the Mechanism of Resistance to Systemic Therapy in Hepatocellular Carcinoma

  2023cites this paper
• CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances

  2023cites this paper
• Correlation of IL-15 with viral load of hepatitis B and its role in the clearance of the virus

  2023influential citation
• Soluble programmed death ligand‐1‐induced immunosuppressive effects on chimeric antigen receptor‐natural killer cells targeting Glypican‐3 in hepatocellular carcinoma

  2023cites this paper
• A Novel TrxR1 Inhibitor Regulates NK and CD8+ T Cell Infiltration and Cytotoxicity, Enhancing the Efficacy of Anti-PD-1 Immunotherapy against Hepatocarcinoma.

  2023cites this paper
• A2AR limits IL-15-induced generation of CD39+ NK cells with high cytotoxicity.

  2023cites this paper
• Chimeric Antigen Receptor-Natural Killer Cells: A New Breakthrough in the Treatment of Solid Tumours.

  2022cites this paper
• CXCL8, CXCL9, CXCL10, and CXCL11 as biomarkers of liver injury caused by chronic hepatitis B

  2022cites this paper
• Immune Microenvironment and Immunotherapeutic Management in Virus-Associated Digestive System Tumors

  2022cites this paper
• Enhanced Delivery of TLR7/8 Agonists by Metal-Organic Frameworks for Hepatitis B Virus Cure.

  2022cites this paper
• Molecular pathogenesis: Connections between viral hepatitis-induced and non-alcoholic steatohepatitis-induced hepatocellular carcinoma

  2022cites this paper
• STAT1 is associated with NK cell dysfunction by downregulating NKG2D transcription in chronic HBV-infected patients.

  2022cites this paper
• Pan-cancer analysis of prognostic and immunological role of DTYMK in human tumors

  2022cites this paper
• Berberine enhances the anti-hepatocellular carcinoma effect of NK92-MI cells through inhibiting IFN-gamma-mediated PD-L1 expression

  2022cites this paper
• Role of Exosomes in Immunotherapy of Hepatocellular Carcinoma

  2022cites this paper
• Combination of Radiofrequency Ablation With Resiquimod to Treat Hepatocellular Carcinoma Via Inflammation of Tumor Immune Microenvironment and Suppression of Angiogenesis

  2022cites this paper
• Efficacy and security of tumor vaccines for hepatocellular carcinoma: a systemic review and meta-analysis of the last 2 decades

  2022cites this paper
• Innate lymphoid cells and cancer

  2022cites this paper
• Current Immunotherapeutic Approaches for Malignant Gliomas

  2022cites this paper
• NAFLD and HBV interplay - related mechanisms underlying liver disease progression

  2022cites this paper
• Clinicopathological and Prognostic Value of Programmed Cell Death 1 Expression in Hepatitis B Virus-related Hepatocellular Carcinoma: A Meta-analysis

  2021cites this paper
• Intratumor Regulatory Noncytotoxic NK Cells in Patients with Hepatocellular Carcinoma

  2021cites this paper
• Natural Killer Cells and Type 1 Innate Lymphoid Cells in Hepatocellular Carcinoma: Current Knowledge and Future Perspectives

  2021cites this paper
• The effects of stereotactic body radiotherapy on peripheral natural killer and CD3+CD56+ NKT-like cells in patients with hepatocellular carcinoma.

  2021cites this paper
• Intravital molecular imaging reveals the restrained capacity of CTLs in the killing of tumor cells in the liver

  2021cites this paper
• Quantitative engineering biology in the tumor microenvironment

  2021cites this paper
• Role of NK Cells in Cancer and Immunotherapy

  2021cites this paper
• Roles of long noncoding RNAs on tumor immune escape by regulating immune cells differentiation and function.

  2021cites this paper
• The Systematic Landscape of Nectin Family and Nectin-Like Molecules: Functions and Prognostic Value in Low Grade Glioma

  2021cites this paper
• CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies

  2021cites this paper
• Innate lymphoid cells and cancer: Role in tumor progression and inhibition

  2021cites this paper
• Magneto-Activation and Magnetic Resonance Imaging of Natural Killer Cells Labeled with Magnetic Nanocomplexes for the Treatment of Solid Tumors.

  2021cites this paper
• Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review

  2021cites this paper
• The Mechanisms of HBV-Induced Hepatocellular Carcinoma

  2021cites this paper
• Berberine enhances the anti-HCC effect of NK cells through inhibiting interferon-gamma-mediated PD-L1 expression

  2021cites this paper
• Metformin Actions on the Liver: Protection Mechanisms Emerging in Hepatocytes and Immune Cells against NASH-Related HCC

  2021cites this paper
• NK Cells in the Pathogenesis of Chronic Obstructive Pulmonary Disease

  2021cites this paper
• Development and Verification of the Hypoxia-Related and Immune-Associated Prognosis Signature for Hepatocellular Carcinoma

  2020cites this paper
• Targeting Natural Killer Cells for Tumor Immunotherapy

  2020cites this paper
• Cytotoxic immune cell-based immunotherapy for hepatocellular carcinoma

  2020cites this paper
• Establishment and Preclinical Therapy of Patient-derived Hepatocellular Carcinoma Xenograft Model.

  2020cites this paper
• Recent advances regarding tumor microenvironment and immunotherapy in hepatocellular carcinoma

  2020influential citation
• Apatinib prevents natural killer cell dysfunction to enhance the efficacy of anti-PD-1 immunotherapy in hepatocellular carcinoma

  2020cites this paper
• Tissue-Resident NK Cells: Development, Maturation, and Clinical Relevance

  2020cites this paper
• Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy

  2020cites this paper
• Induced pluripotent stem cell-derived natural killer cells gene-modified to express chimeric antigen receptor-targeting solid tumors

  2020cites this paper
• Ambiguous roles and potential therapeutic strategies of innate lymphoid cells in different types of tumor

  2020cites this paper
• CAR-NK cells: A promising cellular immunotherapy for cancer

  2020cites this paper